Cited by 408Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorTreatment of Major Depression

The DOI matches its Crossref record, with a small difference in title or year; 85 of the 86 references it cites were found in a registry or an index.

Delayed-Onset Hypothesis of Antipsychotic Action: A Hypothesis Tested and Rejected

Agid, Ofer, Kapur, Shitij, Arenovich, Tamara, Zipursky, Robert B.·2003·Archives of General Psychiatry

DOI 10.1001/archpsyc.60.12.1228

Open this paper in CoChat — free account

Abstract

Context To understand the mechanism of action of antipsychotic drugs, it is critical to recognize the time course over which these medications take effect. Current models of antipsychotic action presume a "delayed onset" of action. Objective To test the delayed-onset hypothesis of antipsychotic action via a meta-analytic study. Data sources and study selection Double-masked studies that reported results from active or placebo-controlled trials of antipsychotic response during the first 4 weeks of treatment were selected. These studies were identified by searching MEDLINE, 1996 to 2001; the Cumulative Index to Nursing and Allied Health, 1982 to 2001; EMBASE, 1980 to 2001; the ACP Journal Club; the Cochrane Database of Systematic Reviews; and the Database of Abstracts of Reviews of Effectiveness. Leads from these sources were followed up by manual searches. Data synthesis Forty-two published studies, including 7450 patients and 119 independent response vs time curves, were identified. Reductions in total scores on the Brief Psychiatric Rating Scale and the Positive and Negative Syndrome Scale were 13.8% during week 1, 8.1% during week 2, 4.2% during week 3, and 4.7% during week 4. This pattern of "early-onset" improvement was present even after the estimated effect of placebo treatment was removed and when results were restricted to the psychotic subscales of the scales. Conclusions This analysis rejects the commonly held hypothesis that antipsychotic response is delayed. Rathe…

Integrity signals

Registry

Crossref · 10.1001/archpsyc.60.12.1228

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Psychosis as a state of aberrant salience: a framework linking biology, phenomenology and pharmacology in schizophrenia
Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813
Self-citation
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Effect of Chlorpromazine or Haloperidol on Formation of 3‐Methoxytyramine and Normetanephrine in Mouse Brain
Carlsson, A., & Lindqvist, M. (1963) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1963.tb01730.x · Cited by 2,156
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial
Tollefson, G. D., Beasley, C. M., Tran, P. V., Street, J. S., Krueger, J. A., Tamura, R., Graffeo, K. A., & Thieme, M. E. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891
A Canadian Multicenter Placebo-Controlled Study of Fixed Doses of Risperidone and Haloperidol in the Treatment of Chronic Schizophrenic Patients
Chouinard, G., Jones, B., Remington, G. J., BLOOM, D., Addington, D. E., MacEwan, G. W., Labelle, A., Beauclair, L., & Arnott, W. S. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199302000-00004 · Cited by 876
Antipsychotic Drugs: Direct Correlation Between Clinical Potency and Presynaptic Action on Dopamine Neurons
Seeman, P., & Lee, T. (1975) · Science · doi:10.1126/science.1145194 · Cited by 869 · cited 3×
“Studies were excluded from this analysis if they (1) included patients younger than 16 years, (2) were specifically targeted at treatment nonresponders or patients with treatmentresistant schizophrenia, ( 3 ) used antipsychotic medications for indications other than psychosis (eg, depressive or anxiety symptoms in a p…”
BackgroundMethodInfluential
Olanzapine versus Placebo and Haloperidol
Beasley, C. M., Tollefson, G. D., Tran, P., SATTERLEE, W. G., Sanger, T. M., & Hamilton, S. H. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00069-p · Cited by 777
Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders
Trân, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C. M., & Tollefson, G. D. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00010 · Cited by 712
Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons
Chiodo, L. A., & Bunney, B. (1983) · Journal of Neuroscience · doi:10.1523/jneurosci.03-08-01607.1983 · Cited by 680
Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activity
Bunney, B. S., & Grace, A. A. (1978) · Life Sciences · doi:10.1016/0024-3205(78)90471-x · Cited by 553
New Oxford Textbook of Psychiatry
Rimes, K. A., & Salkovskis, P. M. (2000) · Oxford University Press eBooks · Cited by 428
Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient
Kapur, S., & Remington, G. J. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01251-3 · Cited by 390
Self-citation
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial
Beasley, C. M., Sanger, T. M., SATTERLEE, W. G., Tollefson, G. D., Tran, P., & Hamilton, S. H. (1996) · Psychopharmacology · doi:10.1007/bf02245617 · Cited by 390
New Oxford Textbook of Psychiatry
(2012) · doi:10.1093/med/9780199696758.001.0001 · Cited by 386
A Randomized Double-Blind Study of Risperidone and Olanzapine in the Treatment of Schizophrenia or Schizoaffective Disorder
Conley, R. R., & Mahmoud, R. A. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.5.765 · Cited by 336
Induction of depolarization block in midbrain dopamine neurons by repeated administration of haloperidol: analysis using in vivo intracellular recording.
Grace, A. A., & Bunney, B. S. (1986) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24386-5 · Cited by 315
Double-Blind, Placebo-Controlled Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in the Treatment of Acute Agitation in Schizophrenia
Wright, P., Birkett, M. A., David, S. R., Meehan, K., Ferchland, I., Alaka, K., Saunders, J. C., Krueger, J., Bradley, P., San, L., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.7.1149 · Cited by 303
Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double‐blind comparative study
Claus, A., Bollen, J., Cuyper, H. D., Eneman, M., Malfroid, M., Peuskens, J., & Heylen, S. (1992) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1992.tb01473.x · Cited by 295
Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs
Grace, A. A., Bunney, B. S., Moore, H. M., & Todd, C. L. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10064-3 · Cited by 284
Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial
Beasley, C. M., Hamilton, S. H., Crawford, A. M., Dellva, M. A., Tollefson, G. D., Trân, P. V., Blin, O., & Beuzen, J. N. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00392-6 · Cited by 275
Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons in the rat
White, F. J., & Wang, R. Y. (1983) · Life Sciences · doi:10.1016/0024-3205(83)90929-3 · Cited by 212
Risperidone: clinical safety and efficacy in schizophrenia.
Borison, R. L., Pathiraja, A., Diamond, B. I., & Meibach, R. C. (1992) · PubMed · Cited by 210
Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations
Høyberg, O. J., Fensbo, C., Lingjærde, O. C., Sloth-Nielsen, M., Salvesen, I., & Remvig, J. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03480.x · Cited by 176
Early nonresponse to fluoxetine as a predictor of poor 8-week outcome
Nierenberg, A. A., McLean, N. E., Alpert, J. E., Worthington, J. J., Rosenbaum, J. F., & D, M. F. M. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.10.1500 · Cited by 172
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
Peuskens, J., Bech, P., Möller, H., Bale, R., Fleurot, O., & Rein, W. (1999) · Psychiatry Research · doi:10.1016/s0165-1781(99)00075-x · Cited by 170
A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia
Copolov, D., Link, C. G. G., & Kowalcyk, B. B. (2000) · Psychological Medicine · doi:10.1017/s0033291799001476 · Cited by 144
CHLORPROMAZINE IN THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS
WINKELMAN, N. W. (1954) · JAMA · doi:10.1001/jama.1954.03690190024007 · Cited by 142
Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol
Möller, H. ‐., Boyer, P., Fleurot, O., & Rein, W. (1997) · Psychopharmacology · doi:10.1007/s002130050361 · Cited by 139
Rapid Treatment of Acute Psychotic Symptoms With High- and Low-Dose Haloperidol
Neborsky, R. J. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780270081011 · Cited by 134
Effect of Chlorpromazine on the Behaviour of Chronically Overactive Psychotic Patients
Elkes, J., & Elkes, C. (1954) · BMJ · doi:10.1136/bmj.2.4887.560 · Cited by 119
Antipsychotic and Anxiolytic Properties of Risperidone, Haloperidol, and Methotrimeprazine in Schizophrenic Patients
Blin, O., Azorin, J. M., & Bouhours, P. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199602000-00007 · Cited by 117
Antipsychotic drug effects on the electrical activity of dopaminergic neurons
Bunney, B. S. (1984) · Trends in Neurosciences · doi:10.1016/s0166-2236(84)80013-2 · Cited by 111
Rapid treatment of acute psychosis
Anderson, W. H., Kuehnle, J. C., & Catanzano, D. M. (1976) · American Journal of Psychiatry · doi:10.1176/ajp.133.9.1076 · Cited by 103
Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group*
Carrière, P., Bonhomme, D., & Lempérière, T. (2000) · European Psychiatry · doi:10.1016/s0924-9338(00)00401-6 · Cited by 100
The depolarization block hypothesis of neuroleptic action: implications for the etiology and treatment of schizophrenia
Grace, A. A. (1992) · Springer eBooks · doi:10.1007/978-3-7091-9211-5_6 · Cited by 98
Double-blind Comparison of Risperidone and Haloperidol in Schizophrenic and Schizoaffective Psychoses
Češková, E., & Švestka, J. (1993) · Pharmacopsychiatry · doi:10.1055/s-2007-1014355 · Cited by 97
Acute high-dose parenteral haloperidol treatment of psychosis
Lerner, Y., Lwow, E., Levitin, A.-L., & Belmaker, R. H. (1979) · American Journal of Psychiatry · doi:10.1176/ajp.136.8.1061 · Cited by 81
Amisulpride Versus Haloperidol in Treatment of Schizophrenic Patients - Results of a Double-Blind Study
Delcker, A., Schoon, M., Oczkowski, B., & Gaertner, H. (1990) · Pharmacopsychiatry · doi:10.1055/s-2007-1014494 · Cited by 79
Sulpiride and Haloperidol in Schizophrenia: A Double-blind Cross-over Study of Therapeutic Effect, Side Effects and Plasma Concentrations
Gerlach, J., Behnke, K., Heltberg, J., Munk‐Andersen, E., & Nielsen, H. (1985) · The British Journal of Psychiatry · doi:10.1192/bjp.147.3.283 · Cited by 71
Clozapine versus chlorpromazine for the treatment of schizophrenia: preliminary results from a double-blind study.
Gelenberg, A. J., & Doller, J. C. (1979) · PubMed · Cited by 70
A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia
Cooper, S. J., Tweed, J. A., Raniwalla, J., Butler, A., & Welch, C. P. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.101003218.x · Cited by 67
Prescription of Antipsychotic Drugs by Office-Based Physicians in the United States, 1989-1997
Hermann, R. C., Yang, D., Ettner, S. L., Marcus, S. C., Yoon, C. S., & Abraham, M. E. (2002) · Psychiatric Services · doi:10.1176/appi.ps.53.4.425 · Cited by 66
Haloperidol dose, plasma levels, and clinical response: a double-blind study [proceedings].
Ericksen, S. E., Sw, H., & Chang, S. (1978) · PubMed · Cited by 57
Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the Japan multicenter, double‐blind olanzapine trial
Ishigooka, J., Inada, T., & Miura, S. (2001) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2001.00882.x · Cited by 56
Loxapine versus haloperidol parenterally in acute psychosis with agitation
Fruensgaard, K., Korsgaard, S., Jørgensen, H., & Jensen, K. (1977) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1977.tb00226.x · Cited by 53
Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial.
Ww, F., Barnas, C., Stuppäck, C., Unterweger, B., Miller, C., & Hinterhuber, H. (1989) · PubMed · Cited by 53
The time course of neuroleptic therapy for psychosis: role of learning processes and implications for concepts of psychotic illness
Miller, R. J. (1987) · Psychopharmacology · doi:10.1007/bf00176470 · Cited by 50
Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias)
Garver, D. L., Kelly, K., Fried, K. A., Magnusson, M., & Hirschowitz, J. (1988) · Psychological Medicine · doi:10.1017/s0033291700009818 · Cited by 50
A controlled dose‐ranging study of remoxipride and haloperidol in schizophrenia ‐ a Canadian multicentre trial
Lapierre, Y. D., Nair, N., Chouinard, G., Awad, A. G., Saxena, B., Jones, B., McClure, D. J., Bakish, D., Max, P., Manchanda, R., et al. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05293.x · Cited by 46
Antipsychotic Drug Use in the United States, 1976-1985
Wysowski, D. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810100071013 · Cited by 44
A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia.
Paprocki, J., & Versiani, M. (1977) · PubMed · Cited by 44
Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients
Glovinsky, D., Kirch, D. G., & Wyatt, R. J. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90124-i · Cited by 41
A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients.
Tuason, V. B. (1986) · PubMed · Cited by 41
Pimozide versus Haloperidol in Acute Schizophrenia. A Double Blind Controlled Study
Haas, S., & Beckmann, H. (1982) · Pharmacopsychiatry · doi:10.1055/s-2007-1019512 · Cited by 41
Depolarization inactivation of dopamine neurons: an artifact?
Mereu, G., Lilliu, V., Vargiu, P., Muntoni, A., Diana, M., & Gessa, G. L. (1995) · Journal of Neuroscience · doi:10.1523/jneurosci.15-02-01144.1995 · Cited by 40
Rapid "Digitalization" of Decompensated Schizophrenic Patients with Antipsychotic Agents
Donlon, P. T., & Tupin, J. P. (1974) · American Journal of Psychiatry · doi:10.1176/ajp.131.3.310 · Cited by 38
Early response to haloperidol treatment in chronic schizophrenia
Stern, R. G., Kahn, R., Harvey, P. D., D, F. A. M., Apter, S. H., & Hirschowitz, J. (1993) · Schizophrenia Research · doi:10.1016/0920-9964(93)90052-k · Cited by 37
The tolerabilitv and efficacv of the atypical neuroleptic remoxipride cokpared with clozapine and haloperidol in acute schizophrenia
Klieser, E., Strauß, W. H., & Lemmer, W. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb05836.x · Cited by 30
A double‐blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia
Laux, G., KIieser, E., Schröder, H. G., Dittmann, V., Unterweger, B., Schutert, H., König, P., Schöny, H. W., Bunse, J., & Beckmann, H. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05303.x · Cited by 30
Effects of Acute and Chronic Neuroleptic Treatment on the Activity of Mid brain Dopamine Neuronsa
Bunney, B. S. (1988) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1988.tb42097.x · Cited by 27
Early response to clozapine in schizophrenia
Stern, R. G., Kahn, R. S., Davidson, M. E., Nora, R. M., & Davis, K. L. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.12.1817 · Cited by 27
A double‐blind multicentre comparison of remoxipride, at two dose levels, and haloperidol
Patris, M., Agussol, P., Alby, J. M., Brion, S., Burnat, G., Castelnau, D., Deluermoz, S., Dufour, H., Ferreri, M., Goudemand, M., et al. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05294.x · Cited by 26
Loxapine succinate: a double-blind comparison with haloperidol and placebo in acute schizophrenics.
Fb, S., Rf, M., & Helwig, H. (1976) · PubMed · Cited by 26
Remoxipride and haloperidol in schizophrenia: a double‐blind multicentre study.
Ahlfors, U. G., Rimón, R., Appelberg, B., Hagert, U., Harma, P., Katila, H., Mahlanen, A., Mehtonen, O., Naukkarinen, H., Outakoski, J., et al. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05298.x · Cited by 24
Failure of chronic haloperidol to induce depolarization inactivation of dopamine neurons in unanesthetized rats
Mereu, G., Lilliu, V., Vargiu, P., Muntoni, A. L., Diana, M., & Gessa, G. L. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)00545-1 · Cited by 23
Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients
den Boer, J. A., Ravelli, D. P., Huisman, J., Öhrvik, J., Verhoeven, W. M. A., & Westenberg, H. G. M. (1990) · Psychopharmacology · doi:10.1007/bf02245748 · Cited by 23
Haloperidol does not produce dopamine cell depolarization-block in paralyzed, unanesthetized rats
Melis, M., Mereu, G., Lilliu, V., Quartu, M., Diana, M., & Gessa, G. L. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01316-4 · Cited by 22
A double‐blind multicentre study comparing remoxipride, controlled release formulation, with haloperidol in schizophrenia
Pflug, B., Bartels, M., Bauer, H., Bunse, J., Gallhofer, B., Haas, S., Kanzow, W. T. H., Klieser, E., Kufferle, B., Stein, D., et al. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05307.x · Cited by 21
History of the Development of Antipsychotic Medication
Frankenburg, F. R. (1994) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30098-4 · Cited by 21
Slow onset of CNS drugs: can changes in protein concentration account for the delay?
Kuhar, M. J., & Joyce, A. R. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01776-4 · Cited by 20
A double‐blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders
Mendlewicz, J., Bleeker, E. D., Cosyns, P. R., Deleu, G., Lotstra, F., Masson, A., Mertens, C., Parent, M., Peuskens, J., Suy, E., et al. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05306.x · Cited by 19
A double‐blind comparative multicentre study of remoxipride and haloperidol in schizophrenia
Lindström, L., Wiesekjren, I. ‐., Struwe, G., Kristjansson, E., Akselsorn, S., Arthur, H., Andersen, T., Lindgren, S., Norman, Q., Naimell, L., et al. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05304.x · Cited by 19
A comparison of the clinical effects of bromperidol, a new butyrophenone derivative, and haloperidol on schizophrenia using a double-blind technique.
Itoh, H. (1985) · PubMed · Cited by 18
Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double-blind, placebo-controlled trial.
Borison, R. L., Sinha, D., Haverstock, S. L., Mc, M., & Diamond, B. I. (1989) · PubMed · Cited by 17
A double blind comparative multicentre study of remoxipride and haloperidol in schizophrenia
Andersen, J., Kørner, A., Østergård, P., Fensbo, C., Birket‐Smith, M., Thiesen, S., Hansen, N. R., Fogh, M., Kristensen, M., Møller‐Nielsen, E. M., et al. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05299.x · Cited by 15
Loxapine versus chlorpromazine in paranoid schizophrenia: a double-blind study.
Tuason, V. B., Escobar, J. I., Garvey, M., & Schiele, B. C. (1984) · PubMed · Cited by 14
Remoxipride and haloperidol in the acute phase of schizophrenia: a double‐blind comparison
Deo, R., Soni, S. D., Rastogi, S., Levine, S., PIant, I., Edwards, J. G., Mitchell, M. J., & Chanas, A. C. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05302.x · Cited by 14
A Double-blind Comparison of Bromperidol and Haloperidol in Newly Admitted Schizophrenic Patients
Brannen, J. O., McEvoy, J., Wilson, W., Petrie, W. M., Ban, T. A., Berney, S., & Schaffer, J. (1981) · Pharmacopsychiatry · doi:10.1055/s-2007-1019585 · Cited by 13
Heterogeneity of schizophrenia: Relationship to latency of neuroleptic response
McDermott, B. E., Sautter, F. J., & Garver, D. L. (1991) · Psychiatry Research · doi:10.1016/0165-1781(91)90109-3 · Cited by 13
A Double-Blind Comparative Multicentre Study of Controlled-Release Remoxipride, Immediate-Release Remoxipride and Haloperidol in Schizophrenia
Hebenstreit, G. F., Laux, G., Schubert, H., Beckmann, H., Amman, J. M. A., Bunse, J., Eikmeier, G., Geretsegger, C., Kanitz, R.-D., Kanzow, W. T. H., et al. (1991) · Pharmacopsychiatry · doi:10.1055/s-2007-1014460 · Cited by 10
Dopamine-receptor-antagonists
(2022) · Reactions Weekly · doi:10.1007/s40278-022-09100-1 · Cited by 10
Short-term double-blind trial of pipothiazine palmitate and haloperidol in the acute phase of schizophrenia.
Bechelli, L., & Navas-Filho, F. (1986) · PubMed · Cited by 8

Sorted by citations

Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
Howes, O. D., McCutcheon, R. A., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,187
Self-citation
The Neurodevelopmental Hypothesis of Schizophrenia, Revisited
Fatemi, S. H., & Folsom, T. D. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn187 · Cited by 860
Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
Antipsychotic medication in schizophrenia: a review
Lally, J., & MacCabe, J. H. (2015) · British Medical Bulletin · doi:10.1093/bmb/ldv017 · Cited by 560
From dopamine to salience to psychosis—Linking biology, pharmacology and phenomenology of psychosis
Kapur, S., Mizrahi, R., & Li, M. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.01.003 · Cited by 512
Self-citation

See all 408

Authors: Agid, O., Kapur, S., Arenovich, T., & Zipursky, R. B.
Affiliations: Centre for Addiction and Mental Health (CA)
ORCID: Agid, Ofer
Kapur, Shitij
Zipursky, Robert B.
Venue: Archives of General Psychiatry
Publisher: American Medical Association (AMA)
Published: 2003-12-01
Volume: 60
Issue: 12
Pages: 1228
ISSN: 0003-990X (ISSN-L)
DOI: 10.1001/archpsyc.60.12.1228
OpenAlex: W2000636120
Cited by: 408
References: 86
Citations by year: 2026: 5 · 2025: 10 · 2024: 9 · 2023: 5 · 2022: 14 · 2021: 8 · 2020: 14 · 2019: 10 · 2018: 21 · 2017: 16 · 2016: 16 · 2015: 20 · 2014: 24 · 2013: 26 · 2012: 31
FWCI: 8.77
Type: journal article
Language: en
Open access: closed
Locations: Archives of General Psychiatry (publishedVersion)
PubMed (publishedVersion)
Research Portal (King's College London) (submittedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: antipsychotic drugs, mechanism of action, schizophrenia, Brief Psychiatric Rating Scale, PANSS, placebo response
MeSH terms: Adolescent, Adult, Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Psychotic Disorders, Time Factors, Antipsychotic Agents, Treatment Outcome, Controlled Clinical Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Delayed-Onset Hypothesis of Antipsychotic Action: A Hypothesis Tested and Rejected

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks